J. Safra Sarasin Holding AG Buys New Shares in Edwards Lifesciences Corporation $EW

J. Safra Sarasin Holding AG purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 13,558 shares of the medical research company’s stock, valued at approximately $1,054,000.

Several other large investors have also added to or reduced their stakes in the company. Econ Financial Services Corp purchased a new position in Edwards Lifesciences during the second quarter worth approximately $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of Edwards Lifesciences by 7.0% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after buying an additional 9,069 shares during the period. OMERS ADMINISTRATION Corp lifted its position in shares of Edwards Lifesciences by 97.3% during the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at $300,000. Finally, Ninety One UK Ltd grew its stake in Edwards Lifesciences by 14.0% in the 3rd quarter. Ninety One UK Ltd now owns 7,908,572 shares of the medical research company’s stock valued at $615,050,000 after acquiring an additional 969,030 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 12th. BTIG Research reaffirmed a “buy” rating and issued a $103.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Piper Sandler reiterated an “overweight” rating and issued a $98.00 price objective (up from $95.00) on shares of Edwards Lifesciences in a report on Tuesday, January 20th. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a report on Tuesday, January 20th. Finally, Truist Financial set a $92.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, December 5th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $96.82.

Edwards Lifesciences Trading Down 2.1%

EW opened at $81.86 on Thursday. The firm has a market capitalization of $47.50 billion, a price-to-earnings ratio of 35.28, a price-to-earnings-growth ratio of 3.22 and a beta of 0.95. The company’s 50 day simple moving average is $84.89 and its two-hundred day simple moving average is $80.94. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the firm earned $0.67 earnings per share. The business’s revenue for the quarter was up 14.7% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,370,184.06. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the transaction, the vice president directly owned 31,870 shares in the company, valued at $2,729,984.20. This trade represents a 26.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 57,824 shares of company stock worth $4,863,323 in the last three months. 0.34% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.